Rallybio Deal History & Licensing Activity
Rallybio is a large biotech headquartered in US. Over the past three years, Rallybio has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Rare Disease
Rallybio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Rallybio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rare disease program | Avenzo | Other | Unknown | collaboration | Jun 1, 2026 |
| rare disease / immunology program | Avenzo Therapeutics | Other | Unknown | collaboration | Jun 1, 2026 |
| next-generation oncology pipeline | Avenzo Therapeutics | ADC | Unknown | acquisition | May 15, 2026 |
Rallybio Pipeline Focus
Therapeutic areas and modalities where Rallybio is most active based on deal history and clinical trial data.
Therapeutic Areas
Rallybio Strategic Signals
Key indicators of Rallybio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Rallybio's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Rallybio Licensing & Deal Activity
Rallybio is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Rallybio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Rallybio include Rare Disease (2 deals and trials), Immunology (2 deals and trials), and Oncology (2 deals and trials). In terms of modality, Rallybio has shown particular interest in other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Rallybio and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Rallybio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.